Literature DB >> 1718425

A protease activity associated with acetylcholinesterase releases the membrane-bound form of the amyloid protein precursor of Alzheimer's disease.

D H Small1, R D Moir, S J Fuller, S Michaelson, A I Bush, Q X Li, E Milward, C Hilbich, A Weidemann, K Beyreuther.   

Abstract

Amyloid deposits in the brains of patients with Alzheimer's disease (AD) contain a protein (beta A4) which is abnormally cleaved from a larger transmembrane precursor protein (APP). APP is believed to be normally released from membranes by the action of a protease referred to as APP secretase. Amyloid deposits have also been shown to contain the enzyme acetylcholinesterase (AChE). In this study, a protease activity associated with AChE was found to possess APP secretase activity, stimulating the release of a soluble 100K form of APP from HeLa cells transfected with an APP cDNA. The AChE-associated protease was strongly and specifically inhibited by soluble APP (10 nM) isolated from human brain. The AChE-associated protease cleaved a synthetic beta A4 peptide at the predicted cleavage site. As AChE is decreased in AD, a deficiency of its associated protease might explain why APP is abnormally processed in AD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718425     DOI: 10.1021/bi00108a027

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.

Authors:  Katsuyoshi Mizukami; Hiroyasu Akatsu; Eric E Abrahamson; Zhiping Mi; Milos D Ikonomovic
Journal:  Neuropathology       Date:  2015-08-21       Impact factor: 1.906

Review 2.  Erythrocyte acetylcholinesterase as biomarker of pesticide exposure: new and forgotten insights.

Authors:  Caio R D Assis; Amanda G Linhares; Mariana P Cabrera; Vagne M Oliveira; Kaline C C Silva; Marina Marcuschi; Elba V M Maciel Carvalho; Ranilson S Bezerra; Luiz B Carvalho
Journal:  Environ Sci Pollut Res Int       Date:  2018-05-24       Impact factor: 4.223

Review 3.  The role of the amyloid protein precursor (APP) in Alzheimer's disease: does the normal function of APP explain the topography of neurodegeneration?

Authors:  D H Small
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

4.  Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease.

Authors:  C I Wright; C Guela; M M Mesulam
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

5.  Cholinesterases colocalize with sites of neurofibrillary degeneration in aged and Alzheimer's brains.

Authors:  M A Morán; E J Mufson; P Gómez-Ramos
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

6.  Variations in Acetylcholinesterase Activity within Human Cortical Pyramidal Neurons Across Age and Cognitive Trajectories.

Authors:  Monica Janeczek; Tamar Gefen; Mehrnoosh Samimi; Garam Kim; Sandra Weintraub; Eileen Bigio; Emily Rogalski; M-Marsel Mesulam; Changiz Geula
Journal:  Cereb Cortex       Date:  2018-04-01       Impact factor: 5.357

7.  Butyrylcholinesterase-Mediated enhancement of the enzymatic activity of trypsin.

Authors:  S Darvesh; R Kumar; S Roberts; R Walsh; E Martin
Journal:  Cell Mol Neurobiol       Date:  2001-06       Impact factor: 5.046

8.  Brain acetylcholinesterase promotes amyloid-beta-peptide aggregation but does not hydrolyze amyloid precursor protein peptides.

Authors:  E O Campos; A Alvarez; N C Inestrosa
Journal:  Neurochem Res       Date:  1998-02       Impact factor: 3.996

9.  Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains.

Authors:  M A Morán; E J Mufson; P Gómez-Ramos
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

10.  Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.

Authors:  M E Appleyard; B McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.